Contemporary concepts of etiology and clinic of polycystic ovarian syndrome

Valentin Irmov, Vesko Stoilov, Petar Petrov, Tanyo Stefanov


Polycystic ovarian syndrome (PCOS) or polycystic ovary syndrome, hyperandrogenic chronic anovulation, hyperandrogenic ovarianism, scleropolitic ovaries, etc. is one of the most common disorders in endocrinological practice and according to the World Healrh Organization (WHO) the most common endocrine disorder in women in reproductive age. In essence, PCOS is a complex of hormonal disorders that affect the whole body of the woman and the ultimate health. It was first described in 1935 by Stein and Leventhal in women with infertility, obesity, hair, amenorrhea and polycystic ovaries. Therefore the condition is also known as Stein-Leventhal's Syndrome. The concept of hyperandrogenic ovarianism is wider, although in the narrow sense it is meant polycystic ovary syndrome (PCOS).


etiology, clinic, cysts, ovaries

Full Text:



Andreeva S., Menstrualni narusheniya pri devoyki s nadnormeno teglo v pubertetno-yunosheska vazrast. Disertatsionen trud, Sofiya, 2012.

Kamenov, Z., Orbetsova M., Gateva A., Sindrom na polikistoznite yaychnitsi , Sofiya 2010.

Kolarov G., Orbetsova M., Polikistozen ovarialen sindrom, Sofiya 2004.

Kolarov G., Orbetsova M., Praktichesko rakovodstvo za diagnoza i lechenie na polikistozniya ovarialen sindrom, Sofiya 2005.

Mitkov M., Varhu sindroma na polikistoznite yaychnitsi – klinichni i hormonalni harakteristiki i rezultati ot prodalzhitelna konservativna terapiya., Disertatsionen trud, Plovdiv, 2006.

Petrov, P., E. Karaslavova, D. Todorova. Nay-chesti prichini vodeshti do spontanni aborti. Sestrinsko delo, tom 40 2008.

Petrov P., Vavedenie v reproduktivnata meditsina, Plovdiv, Amart 2010.

Pehlivanov B., Klinichni i mediko-sotsialni aspekti na sindroma na polikistoznite yaychnitsi, Plovdiv, 2006.

Robeva R., Nyakoi nevroendokrinni aspekti na gonadnite narusheniya pri sastoyaniya na insulinova rezistentnost, Disertatsionen trud, Sofiya 2008.

Ardaems Y et al. PCOD: contribution of vaginal endosonography and reassessment of ultrasonic diagnosis, 1991;55, 1062-1068.

Cate RL, Mattaliano RJ, Hession C, Tizard R, Farber NM, Cheung A, Ninfa EG, Frey AZ, Gash DJ, Chow EP (June 1986). "Isolation of the bovine and human genes for Müllerian inhibiting substance and expression of the human gene in animal cells". Cell 45 (5): 685–98.

Behringer RR (1994). 5 The in Vivo Roles of Müllerian-inhibiting Substance. "The in vivo roles of müllerian-inhibiting substance". Curr. Top. Dev. Biol. Current Topics in Developmental Biology 29: 171–87.

Hampl, R.; Šnajderová, M.; Mardešić, T. (2011). "Antimüllerian hormone (AMH) not only a marker for prediction of ovarian reserve". Physiological research / Academia Scientiarum Bohemoslovaca 60 (2): 217–223.

Imbeaud S, Faure E, Lamarre I, Mattéi MG, di Clemente N, Tizard R, Carré-Eusèbe D, Belville C, Tragethon L, Tonkin C, Nelson J, McAuliffe M, Bidart JM, Lababidi A, Josso N, Cate RL, Picard JY (December 1995). "Insensitivity to anti-müllerian hormone due to a mutation in the human anti-müllerian hormone receptor". Nat. Genet. 11 (4): 382–8.

Walter F., PhD. Boron (2003). Medical Physiology: A Cellular And Molecular Approaoch. Elsevier/Saunders. p. 1300. ISBN 1-4160-2328-3.

An Introduction to Behavioral Endocrinology, Randy J Nelson, 3rd edition, Sinauer.

Kelsey TW, Wright P, Nelson SM,Anderson RA, Wallace WHB (2011). "A validated model of serum anti-Müllerian hormone from conception to menopause". In Vitzthum, Virginia J. PLoS ONE 6 (7): e22024. doi:10.1371/journal.pone.0022024. PMC 3137624. PMID 21789216.

Weenen C, Laven J, Von Bergh A, Cranfield M, Groome N, Visser J, Kramer P, Fauser B, Themmen A (2004). "Anti-Müllerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment" (abstract). Mol Hum Reprod 10 (2): 77–83. doi:10.1093/molehr/gah015. PMID 14742691.

Broer SJ at al (2011). "Anti-müllerian hormone predicts menopause: a long-term follow-up study in normoovulatory women". J Clin Endocrinol Metab 96 (8): 2532–9. doi:10.1210/jc.2010-2776. PMID 21613357.

Visser J, de Jong F, Laven J, Themmen A (2006). "Anti-Müllerian hormone: a new marker for ovarian function". Reproduction 131 (1): 1–9. doi:10.1530/rep.1.00529. PMID 16388003.

Broer SL, van Disseldorp J, Broeze KA, Dolleman M, Opmeer BC, Bossuyt P, Eijkemans MJ, Mol BW, Broekmans FJ (2013). "Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach". Human Reproduction Update 19 (1): 26–36. doi:10.1093/humupd/dms041. PMID 23188168. Retrieved 2013-04-23.

Trbovich AM, Martinelle N, O'Neill FH, Pearson EJ, Donahoe PK, Sluss PM, Teixeira J (October 2004). "Steroidogenic activities in MA-10 Leydig cells are differentially altered by cAMP and Müllerian inhibiting substance". The Journal of Steroid Biochemistry and Molecular Biology 92 (3): 199–208. doi:10.1016/j.jsbmb.2004.07.002. PMID 15555913.

Wang PY, Protheroe A, Clarkson AN, Imhoff F, Koishi K, McLennan IS (April 2009). "Müllerian inhibiting substance contributes to sex-linked biases in the brain and behavior". Proceedings of the National Academy of Sciences of the United States of America 106 (17): 7203–8. doi:10.1073/pnas.0902253106. PMC 2678437. PMID 19359476.

La Marca, A.; Sunkara, S. K. (2013). "Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: From theory to practice". Human Reproduction Update 20: 124.

Hampl, R.; Šnajderová, M.; Mardešić, T. (2011). "Antimüllerian hormone (AMH) not only a marker for prediction of ovarian reserve". Physiological research / Academia Scientiarum Bohemoslovaca 60 (2): 217–223. PMID 21114374. edit

Dennis NA, Houghton LA, Jones GT, van Rij AM, Morgan K, McLennan IS (July 2012). "The level of serum anti-Müllerian hormone correlates with vitamin D status in men and women but not in boys". The Journal of Clinical Endocrinology and Metabolism 97 (7): 2450–5. doi:10.1210/jc.2012-1213. PMID 22508713. Retrieved 2013-04-23.

Cupisti S, Dittrich R, Mueller A, Strick R, Stiegler E, Binder H, Beckmann MW, Strissel P (December 2007). "Correlations between anti-müllerian hormone, inhibin B, and activin A in follicular fluid in IVF/ICSI patients for assessing the maturation and developmental potential of oocytes". Eur. J. Med. Res. 12 (12): 604–8.

Seifer DB, Maclaughlin DT (September 2007). "Mullerian Inhibiting Substance is an ovarian growth factor of emerging clinical significance". Fertil. Steril. 88 (3): 539–46. doi:10.1016/j.fertnstert.2007.02.014. PMID 17559842.

Wallace WHB, Kelsey TW (2004). "Ovarian reserve and reproductive age may be determined from measurement of ovarian volume by transvaginal sonography". Human Reproduction 19 (7): 1612–7. doi:10.1093/humrep/deh285. PMID 15205396.

Nelson SM, Yates RW et al. (2007). "Serum anti-Mullerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles—implications for individualization of therapy". Human Reproduction 22 (9): 2414–2421. doi:10.1093/humrep/dem204. PMID 17636277.


  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.